Stock Analysis:Baxalta Inc (NYSE:BXLT) Stock Target Has Just Been Increased
In a recent research report revealed by Barclays Capital on Wednesday, 9 December, Baxalta Inc (NYSE:BXLT) had its PT hiked to $40.00. The firm presently has a solid “Equal Weight” rating on shares.
From a total of 4 analysts covering Baxalta (NYSE:BXLT) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $47 while the lowest target price is $38. The mean of all analyst targets is $42.5 with a 7.56% above today’s ($37.19) stock price. Baxalta was the topic of 3 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. William Blair initiated shares on August 17 with “Outperform” rating. Credit Suisse reinitiated BXLT stock in a recent report from August 10 with “Outperform” rating.
Approximately 3.68 million shares of stock traded hands or 27.34% up from the average. Baxalta Inc (NYSE:BXLT) has risen 6.00% since November 9, 2015 and is uptrending. It has outperformed by 6.80% the S&P500.
Baxalta Incorporated is a biopharmaceutical company. The company has a market cap of $24.92 billion. The Firm develops, makes and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. It has 21.75 P/E ratio. The Firm also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars.
According to Zacks Investment Research, “Baxalta Incorporated is a biopharmaceutical company which is engaged in developing, manufacturing and commercializing transformative therapies to treat orphan and underserved disease conditions in hematology, immunology and oncology. Baxalta Incorporated is based in Deerfield, United States.” Get a free copy of the Zacks research report on Baxalta Inc (BXLT).